Interval Training Study in Psoriatic Arthritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02995460|
Recruitment Status : Completed
First Posted : December 16, 2016
Last Update Posted : November 13, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Psoriatic arthritis is a chronical inflammatory disease characterized by pain and reduced physical function. Patients have a higher risk of cardiovascular disease and a higher body mass index.
A pilot study in patients with rheumatoid arthritis has shown positive effect on inflammation after 12 weeks of high-intensity interval training.
The primary aim of this study is to determine whether high-intensity interval training affects the disease activity in psoriatic arthritis. This intervention is believed to result in benefits in terms of inflammation, body composition and risk factors for cardiovascular disease.
|Condition or disease||Intervention/treatment||Phase|
|Psoriatic Arthritis||Behavioral: interval training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Interval Training Study in Psoriatic Arthritis|
|Actual Study Start Date :||January 2013|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
Experimental: interval training
4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
Behavioral: interval training
4x4 high intensity interval training
No Intervention: controls
No change in diet and training habits
- Patient global assesment (PGA) [ Time Frame: Baseline, 3 months (right after intervention), 9 months ]PGA is measured as a change between timepoints. PGA is registered by the patient on a visual analog scale.
- Maximal oxygen uptake (VO2 max) [ Time Frame: Baseline, 3 months (right after intervention), 9 months ]The VO2 max is measured as a change between timepoints
- Total lean mass [ Time Frame: Baseline, 3 months (right after intervention), 9 months ]Total lean mass is measured as a change between timepoints and is measured by dual energy x-ray absorptiometry (DXA).
- Total body fat [ Time Frame: Baseline, 3 months (right after intervention), 9 months ]Total body fat is measured as a change between timepoints and is measured by dual energy x-ray absorptiometry (DXA).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- fulfilling the CASPAR criteria of psoriatic arthritis
- ability to exercise.
- Inability to exercise
- very high disease Activity
- unstable ischemic cardiovascular disease
- severe pulmonary disease
- drug- and alcohol addictions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02995460
|Study Director:||Siri Forsmo, md prof||Norwegian University of Science and Technology|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Norwegian University of Science and Technology|
|Other Study ID Numbers:||
|First Posted:||December 16, 2016 Key Record Dates|
|Last Update Posted:||November 13, 2018|
|Last Verified:||November 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Skin Diseases, Papulosquamous